Baloxavir marboxil as a new specific anti-influenza drug
Open Access
- 21 January 2023
- journal article
- research article
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (4) , 245-254
Abstract
Baloxavir marboxil is the first antiviral drug with a unique single dose, registered in Russia in September 2020 under the trade name Xoflusa, for treating infection caused by influenza A and B viruses. This article presents an overview of studies on the anti-influenza activity of baloxavir marboxil by foreign colleagues. Data from scientific articles by different authors were analyzed and in vitro results and clinical data were considered, which can help in making recommendations for the use of the drug for the treatment and postexposure prophylaxis of influenza. Baloxavir marboxil acts as a selective low-molecular-weight inhibitor of an enzyme specific to the influenza virus in the viral RNA polymerase complex and is effective against strains resistant to oseltamivir. In the combined phenotypic analysis and analysis based on the sequence in the polymerase acidic (PA) protein, the frequency of viruses showing reduced susceptibility to the drug remains low. Numerous studies have demonstrated the safety profile and productivity of influenza treatment in various groups (without risk factors and high-risk patients). Baloxavir marboxil stops the replication of the influenza virus in the early stages, which terminates its release during the first day and significantly relieves the patients condition on the second day. Monitoring of the antiviral activity of the drug, especially in children aged 12 years and people with weakened immunity, should be closely monitored to develop clinical recommendations and prevent the formation of substitutions I38(T/F/M/S/L/V) in the PA of influenza A and B viruses that reduce their sensitivity to the drug.Keywords
This publication has 31 references indexed in Scilit:
- Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease InhibitorsmBio, 2018
- Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information StudyInfluenza and Other Respiratory Viruses, 2017
- Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza VirusesPLOS Pathogens, 2014
- Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 VirusIn Vitro, in Mice and in FerretsJournal of Virology, 2014
- Enhanced Mammalian Transmissibility of Seasonal Influenza A/H1N1 Viruses Encoding an Oseltamivir-Resistant NeuraminidaseJournal of Virology, 2012
- Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) VirusesPLOS Pathogens, 2011
- Neuraminidase of 2007–2008 Influenza A(H1N1) Viruses Shows Increased Affinity for Sialic Acids Due to the D344N SubstitutionAntiviral Therapy, 2011
- Oseltamivir-resistant pandemic H1N1 influenzaCanadian Medical Association Journal, 2011
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- Structure of the catalytic and antigenic sites in influenza virus neuraminidaseNature, 1983